Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array

Journal of Virological Methods

Volumn 175, Issue 1, 2011, Pages 1-6

  Liu, Hongyan ^a   Mao, Richeng ^a   Fan, Lili ^b   Xia, Jiahui ^b   Li, Yiliang ^b   Yin, Yongxi ^b   Li, Xinyan ^a   Zhao, Xu ^a   Guo, Hongying ^a   Zhu, Haoxiang ^a   Zhang, Yongmei ^a   Kang, Yaoyue ^a   Zhang, Jiming ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Fudan zhang Jiang Bio Pharmaceutical Corporation   (China)

Author keywords

Beads or microspheres; Chronic hepatitis B; Hepatitis B virus; Lamivudine or adefovir resistance; Liquid array; Luminex

Indexed keywords

ADEFOVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; PROTEIN ARRAY ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

HEPATITIS B VIRUS;

EID: 79957979661     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.04.005     Document Type: Article

References (31)

1. Allen M.I., Gauthier J., DesLauriers M., Bourne E.J., Carrick K.M., Baldanti F., Ross L.L., Lutz M.W., Condreay L.D. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J. Clin. Microbiol. 1999, 37:3338-3347.
2. Boving M.K., Pedersen L.N., Moller J.K. Eight-plex PCR and liquid-array detection of bacterial and viral pathogens in cerebrospinal fluid from patients with suspected meningitis. J. Clin. Microbiol. 2009, 47:908-913.
3. Chayama K., Suzuki Y., Kobayashi M., Tsubota A., Hashimoto M., Miyano Y., Koike H., Koida I., Arase Y., Saitoh S., Murashima N., Ikeda K., Kumada H. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998, 27:1711-1716.
4. Degertekin B., Hussain M., Tan J., Oberhelman K., Lok A.S. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J. Hepatol. 2009, 50:42-48.
5. Degertekin B.A.S.L. Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?. J. Hepatol. 2008, 48:892-894.
6. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., Laras A., Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000, 32:847-851.
7. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Ma J., Arterburn S., Xiong S., Currie G., Brosgart C.L. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2005, 352:2673-2681.
8. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Ma J., Brosgart C.L., Borroto-Esoda K., Arterburn S., Chuck S.L. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-1751.
9. Hong S.P., Kim N.K., Hwang S.G., Chung H.J., Kim S., Han J.H., Kim H.T., Rim K.S., Kang M.S., Yoo W., Kim S.O. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J. Hepatol. 2004, 40:837-844.
10. Hussain M., Fung S., Libbrecht E., Sablon E., Cursaro C., Andreone P., Lok A.S. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J. Clin. Microbiol. 2006, 44:1094-1097.
11. Jang H., Cho M., Heo J., Kim H., Jun H., Shin W., Cho B., Park H., Kim C. Oligonucleotide chip for detection of lamivudine-resistant hepatitis B virus. J. Clin. Microbiol. 2004, 42:4181-4188.
12. Kim J.-K., Lee H.-J., Lee Y.-J., Chun J.-Y., Lee I.-K., Lim Y.-S., Suh D.J., Ko S.-Y., Kim M.H., Oh H.-B. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J. Virol. Methods 2008, 149:76-84.
13. Kirishima T., Okanoue T., Daimon Y., Itoh Y., Nakamura H., Morita A., Toyama T., Minami M. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J. Hepatol. 2002, 37:259-265.
14. Lampertico P., Vigano M., Manenti E., Iavarone M., Lunghi G., Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005, 42:1414-1419.
15. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., Tanwandee T., Tao Q.M., Shue K., Keene O.N., Dixon J.S., Gray D.F., Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004, 351:1521-1531.
16. Lindstrom A., Odeberg J., Albert J. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J. Clin. Microbiol. 2004, 42:4788-4795.
17. Lupo J., Larrat S., Hilleret M.N., Germi R., Boyer V., Nicod S., Bargues G., Leroy V., Seigneurin J.M., Zarski J.P., Morand P. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. J. Virol. Methods 2009, 156:52-58.
18. Malmstrom S., Hannoun C., Lindh M. Mutation analysis of lamivudine resistant hepatitis B virus strains by TaqMan PCR. J. Virol. Methods 2007, 143:147-152.
19. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., Germanidis G., Lee S.S., Flisiak R., Kaita K., Manns M., Kotzev I., Tchernev K., Buggisch P., Weilert F., Kurdas O.O., Shiffman M.L., Trinh H., Washington M.K., Sorbel J., Anderson J., Snow-Lampart A., Mondou E., Quinn J., Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008, 359:2442-2455.
20. Margeridon-Thermet S., Shulman N.S., Ahmed A., Shahriar R., Liu T., Wang C., Holmes S.P., Babrzadeh F., Gharizadeh B., Hanczaruk B., Simen B.B., Egholm M., Shafer R.W. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J. Infect. Dis. 2009, 199:1275-1285.
21. Osiowy C., Villeneuve J.P., Heathcote E.J., Giles E., Borlang J. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J. Clin. Microbiol. 2006, 44:1994-1997.
22. Pas S.D., Tran N., de Man R.A., Burghoorn-Maas C., Vernet G., Niesters H.G. Comparison of reverse hybridization, microarray, and sequence analysis for genotyping hepatitis B virus. J. Clin. Microbiol. 2008, 46:1268-1273.
23. Pawlotsky J.M., Dusheiko G., Hatzakis A., Lau D., Lau G., Liang T.J., Locarnini S., Martin P., Richman D.D., Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405-415.
24. Punia P., Cane P., Teo C.-G., Saunders N. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J. Hepatol. 2004, 40:986-992.
25. Schildgen O., Sirma H., Funk A., Olotu C., Wend U.C., Hartmann H., Helm M., Rockstroh J.K., Willems W.R., Will H., Gerlich W.H. Variant of hepatitis B virus with primary resistance to adefovir. New Engl. J. Med. 2006, 354:1807-1812.
26. Solmone M., Vincenti D., Prosperi M.C., Bruselles A., Ippolito G., Capobianchi M.R. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J. Virol. 2009, 83:1718-1726.
27. Tran N., Berne R., Chann R., Gauthier M., Martin D., Armand M.A., Ollivet A., Teo C.G., Ijaz S., Flichman D., Brunetto M., Bielawski K.P., Pichoud C., Zoulim F., Vernet G. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J. Clin. Microbiol. 2006, 44:2792-2800.
28. Wang R.S., Zhang H., Zhu Y.F., Han B., Yang Z.J. Detection of YMDD mutants using universal template real-time PCR. World J. Gastroenterol. 2006, 12:1308-1311.
29. Wright T.L. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin. Liver Dis. 2004, 24(Suppl. 1):31-36.
30. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785-791.
31. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 139:1593-1608.